Psoriasis

A recent study illustrated the benefits of tildrakizumab for patients with psoriasis with comorbid metabolic syndrome.

A recent case series examined clinical and radiographic characteristics of patients with concomitant psoriasis and interstitial lung disease (ILD).

Patients with severe psoriasis have an increased risk of dying from liver, esophageal, and pancreatic cancers, and people with psoriasis have an overall increased risk of a variety of other cancers, according to a meta-analysis and review published Wednesday in JAMA Dermatology.

Steven R. Feldman, MD, PhD, professor of dermatology, Wake Forest School of Medicine, discusses how some drugs for psoriasis are less effective in the presence of metabolic syndrome.

Previous work has linked psoriasis and nonalcoholic fatty liver disease, but this is one of the first studies to tie together the severity of the 2 conditions.

Steven R. Feldman, MD, PhD, professor of dermatology, Wake Forest School of Medicine, discusses the challenges clinicians face when managing psoriasis in patients who also have metabolic syndrome.

Knowing who may respond to tildrakizumab early on may help providers and patients decide whether to continue with treatment, the researchers said.

Patients with psoriasis who were treated with biologics were less likely to develop psychiatric illnesses compared with patients not treated with biologics; however, the researchers did note treatment selection may have influenced the findings.

Measurement of drug levels early in treatment with ustekinumab for patients with psoriasis may be able to successfully predict patient response and, therefore, direct a treatment strategy.

Psoriasis is known to be linked with metabolic syndrome, which is triggered by chronic inflammation and fosters obesity and dyslipidemia. A recent study looked at another chronic inflammatory skin disease, lichen planus, to better understand any associations with metabolic syndrome.